If you work with Evaluate, you’ll probably be familiar with our delightful Customer Success team. They’re the people who help ensure that our customers can use our solutions to navigate...
When a biotech or biopharma’s flagship asset is ready for out-licensing, which strategies will get it noticed by the right partners? To gain the attention of larger players, companies need...
For pharma companies, biotech assets present significant opportunities to strengthen pipelines with reduced risk. However, with such a vast ecosystem, identifying the right assets that align with your strategy can...
In the ever-evolving landscape of biopharma and biotech, competitive intelligence (CI) plays a crucial role in driving strategic decisions and maintaining a competitive edge. At the recent Pharma CI conference...
If there’s one thing that the experts at Evaluate love, it’s rummaging around in data to identify trends in the pharma market. One area that is always fascinating to explore...
Volume is up but value is down. That’s the headline of the dealmaking scene for the first half of 2024. There’s not been a mega-merger in the vein of 2023’s...